Friday, 22 September 2017

NATCO receives FDA approval for Vidaza for USA market

28 June 2017 | News

Vidaza is anti-cancer chemotherapy drug that is used for myelodysplastic syndrome (MDS)

Source: Pixabay

Source: Pixabay

Natco pharma limited has announced the final approval for Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Azacitidine for Injection, a generic version of Vidaza by Celgene Corporation.

Vidaza is anti-cancer chemotherapy drug that is used for myelodysplastic syndrome (MDS). Vidaza generated total combined sales of $188 million for the twelve-month period ending April, 2017, based on industry sales data.

According to the notification given on company’s website, “NATCO and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the USA market in the near future”

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Does primary healthcare in India needs prioritization?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls